Jeffrey L. Cummings, MD, is currently Director of both the Deane F. Johnson Center for Neurotherapeutics at UCLA, and the UCLA Alzheimer's Disease Center. He holds the Augustus Rose Professor of Neurology chair, was the Shrinavasan Lecturer in 2004 and the Henderson Lecturer in 2005.
Preface J. L. Cummings; Introduction to neurotherapeutics and
neuropharmacology J. L. Cummings; 1. Rivastigmine in the treatment of
dementia associated with Parkinson's disease: a randomized, double-blind,
placebo-controlled study S. Tekin and R. Lane; 2. Modafinil for the
treatment of fatigue in multiple sclerosis B. Stankoff, C. Lubetzki and M.
Clanet; 3. Radiotherapy with concurrent and adjuvant temozolomide: a new
standard of care for glioblastoma multiform W. P. Mason, R. O. Mirimanoff
and R Stupp; 4. Treating migraine attacks ASAP: concept and methodological
issues N. J. Wiendels and M. D. Ferrari; 5. Early phase trials of
minocycline in amyotropic lateral sclerosis P. H. Gordon, J. Choi, D. H.
Moore and R. G. Miller; 6. Creatine as a potential treatment for
amyotrophic lateral sclerosis J. M. Shefner; 7. AVP-923 as a novel
treatment for pseudobulbar affect ALS L. E. Pope; 8. Liquid fluoxetine vs.
placebo for repetitive behaviors in childhood autism E. Hollander, E.
Swanson, E. Anagnostou, A. Phillips, W. Chaplin and S. Wasserman; 9.
Testing multiple novel mechanisms for treating schizophrenia in a single
trial H. Y. Meltzer; 10. Selegiline in the treatment of negative symptoms
of schizophrenia A. Lin and A. Bodkin; 11. Analysis of the cognitive
enhancing effects of modafinil in schizophrenia D. C. Turner and B. J.
Sahakian; 12. Efficacy and tolerability of ziprasidone and olanzapine in
acutely ill inpatient with schizophrenia or schizoaffective disorder:
results of a double-blind, 6-week study, with a 6-month, double-blind,
continuation phase G. M. Simpson, A. Loebel, L. Warrington and R. Yang.
